A Phase IB/II Multi-cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
To evaluate the efficacy and safety of targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with recurrent and/or persistent endometrial cancer.
DiagnosisPatients who have endometrial cancer that has spread to other parts of the body and/or the disease returned or got worse during or after treatment with chemotherapy.
Recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Cohort 1: Atezolizumab plus Bevacizumab
Cohort 2: Atezolizumab plus Ipatasertib
Cohort 3: Atezolizumab plus Talazoparib
Cohort 4: Atezolizumab plus Trastuzumab emtamsine
Cohort 5: Atezolizumab plus Tiragolumab
The duration of this is study is 48 months.
After completion of study treatment, the doctor will continue to follow up with the patient every 3 months.
For more information, visit Clinicaltrials.gov